If you are Pregnant, Please read this before taking Blokium!
Although no evidence of teratogenecity has been found in animal studies, administration of Bloklum (Atenolol) during pregnancy should be avoided, unless the benefits outweigh the possible risks. Blokium (Atenolol) crosses the placental barrier and appears in the cord blood. No studies have been performed on the use of Blokium (Atenolol) in the first trimester and the possibility of foetal injury cannot be excluded. Administration of Blokium (Atenolol) to pregnant women in the management of mild to moderate hypertension has been associated with intrauterine growth retardation. Therefore benifits must be weighed against possible risk associated with the treatment. There is a significant accumulation of Blokium (Atenolol) in breast milk.
PATIENT WITH BRONCHOSPASTIC DISEASE SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS.
Because of its relative beta 1 -selectivity, however, Blokium may be used with caution in patients with bronchospastic disease who do not respond to or cannot tolerate, other antihypertensive treatment. Since betal -selectivity is not absolute, the lowest possible dose of Blokium should be used and a beta2- stimulating agent (bronchodilator) should be made available. If dosage must be increased, dividing the dose should be considered in order to achieve lower peak blood levels.
Should intoxication occur, excessive bradycardia may be counteracted by Atroppine (1-2 mg i.v.) followed by, if necessary, a beta-stmulant such as Isoprenaline (5-50 mcg/min i.v.).